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Background: Phosphatase and tensin homolog (PTEN) acts as a tumor suppressor gene. Inactivation of PTEN 
has been reported in various types of cancers. PTEN promoter methylation possibly underlies PTEN inactivation, 
which results in tumorigenesis. The aim of this study was to investigate whether PTEN promoter methylation 
contributes to PTEN inactivation in ameloblastoma and its associated protein expression.
Material and Methods: In total, 20 fresh-frozen ameloblastoma samples were evaluated for PTEN promoter meth-
ylation using methylation-specific polymerase chain reaction (MS-PCR).  A subset of 10 paraffin-embedded am-
eloblastoma samples was examined for PTEN expression through immunohistochemistry. Four primary cultured 
ameloblastoma cells were investigated for PTEN promoter methylation and PTEN transcriptional expression via 
reverse transcription PCR.
Results: PTEN promoter methylation was detected in 65% (13/20) of the ameloblastoma samples. Of 10 amelo-
blastoma samples, 4 exhibited reduced PTEN expression. Of 5 samples with methylated PTEN, 3 (60%) were 
associated with loss of PTEN expression. However, PTEN expression was detected in 4 (80%) of 5 samples with 
unmethylated PTEN. In addition, 3 (75%) of 4 primary ameloblastoma cell cultures exhibited an inverse correla-
tion between PTEN promoter methylation and PTEN transcription level.
Conclusions: PTEN promoter methylation is found in a number of ameloblastomas but not significantly correlated 
with loss of PTEN expression. Genetic or epigenetic mechanisms other than PTEN promoter methylation may 
contribute to PTEN inactivation in ameloblastoma tumor cells.
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has been suggested to be involved in tumorigenesis (6-
8). In ameloblastic tumors, PTEN displayed high fre-
quent allelic loss (62%) (9). In addition, PTEN has been 
reported to be completely absent in 33.3% of ameloblas-
toma cases (10). We hypothesized that PTEN promoter 
methylation results in decreased PTEN expression in 
this odontogenic tumor. The aim of this study was to ex-
amine PTEN expression and investigate whether PTEN 




Fresh-frozen samples were obtained from 20 patients 
with ameloblastoma from the Department of Oral and 
Maxillofacial Surgery, Faculty of Dentistry, Mahidol 
University between January 2018 and January 2019. 
Some parts of the specimens were fixed in 10% buffered 
formalin for hematoxylin and eosin staining. Histopath-
ological diagnosis of solid/multicystic ameloblastoma 
was performed by two oral pathologists (PL and NK). 
Furthermore, a cohort study was performed wherein 4 
fresh solid/multicystic ameloblastoma tissue samples 
were harvested to form a primary cell culture. Table 1 
displays the detailed demographic data.
Introduction
Ameloblastoma is the most frequently encountered neo-
plasm arising from the epithelium of the tooth-forming 
apparatus. Although this tumor is benign, it exhibits lo-
cally invasive behavior and has a high risk of recurrence. 
Its macroscopic features range from completely solid to 
multicystic appearance. Its histopathological subtypes 
include follicular, plexiform, acanthomatous, granular 
cell, basal cell, and desmoplastic ameloblastomas. In 
rare cases, ameloblastoma may metastasize despite its 
benign histology; this type of ameloblastoma is termed 
as metastasizing ameloblastoma (1). Ameloblastic car-
cinoma, a malignant counterpart of ameloblastoma, is 
markedly rare, with only 100 cases reported to date; this 
tumor exhibits cytological features of malignancy and 
may or may not metastasize (2).
Phosphatase and tensin homolog (PTEN) is located on 
chromosome 10q23.3 and has been implicated in many 
familial and sporadic cancers (3,4). Deletions or somatic 
mutations in PTEN have been detected in many types of 
cancers, including prostate, breast, and brain cancer (3). 
Apart from genetic mutation, the epigenetic regulation 
of PTEN via differential methylation may contribute to 
its inactivation (5). Methylation of the PTEN promoter 
region has been reported in some types of cancers and 
Ameloblastoma tissue







AM1 Female 30 Mandible Plexiform Unmet Postive 
AM2 Male 63 Mandible Plexiform Met Postive 
AM3 Female 47 Mandible Plexiform Met Negative
AM4 Male 11 Maxilla Plexiform Unmet Postive 
AM5 Female 60 Mandible Follicular Unmet Postive 
AM6 Male 66 Mandible Plexiform Met Postive 
AM7 Male 23 Mandible Follicular Met Negative
AM8 Male 51 Mandible Follicular Unmet Negative
AM9 Male 51 Mandible Follicular Met Negative
AM10 Female 25 Mandible Follicular Unmet Postitive
AM11 Male 59 Mandible Plexiform Met Not available
AM12 Male 44 Maxilla Plexiform Met Not available
AM13 Female 24 Maxilla Plexiform Unmet Not available
AM14 Male 54 Mandible Follicular Unmet Not available
AM15 Female 54 Mandible Plexiform Met Not available
AM16 Male 73 Mandible Plexiform Met Not available
AM17 Female 8 Mandible Plexiform Met Not available
AM18 Male 66 Mandible Follicular Met Not available
AM19 Male 50 Mandible Follicular Met Not available
AM20 Male 50 Maxilla Follicular Met Not available
Ameloblastoma primary cell culture







A1C Female 30 Maxilla Follicular Unmet Postitve
A2C Male 37 Mandible Follicular Unmet Postitve
A3C Female 42 Mandible Plexiform Met Negative
A4X Male 20 Mandible Plexiform Unmet Postitve
Table 1: Detailed data of phosphatase and tensin homolog (PTEN) promoter methylation, PTEN expression in ameloblastoma and demographic data.
e483
Med Oral Patol Oral Cir Bucal. 2020 Jul 1;25 (4):e481-7. PTEN promoter methylation in ameloblastoma
The cultures were grown in Dulbecco’s modified Ea-
gle’s medium supplemented with 10% fetal bovine se-
rum (Invitrogen, Carlsbad, CA, USA) and maintained 
for 3-4 passages prior to DNA extraction.
- DNA extraction, bisulfite modification, and methyla-
tion-specific polymerase chain reaction (MS-PCR)
Genomic DNA was extracted using 10% sodium do-
decyl sulfate buffer and proteinase K at 50°C overnight, 
followed by phenol/chloroform extraction and ethanol 
precipitation. Subsequently, the obtained DNA was air 
dried, dissolved in distilled water, and quantified using 
a NanoDrop spectrophotometer (ND-1000 Spectropho-
tometer; NanoDrop Technologies, Wilmington, DE, 
USA). An optical density (at 260/280 ratio) of >1.8 is 
acceptable for DNA purity and PCR. Next, the DNA 
samples were converted by sodium bisulfite treatment 
using the EZ DNA Methylation-GoldTM kit (Zymo Re-
search, Irvine, CA, USA), as per the manufacturer’s in-
structions.
The bisulfite-treated DNA samples were then subjected 
to MS-PCR using primers specific for either the methyl-
ated or unmethylated forms of PTEN: 1) PTEN methylat-
ed sequence, forward 5′-GTTTGGGGATTTTTTTTTC-
GC-3′ and reverse 5′-AACCCTTCCTACGCCGCG-3′ 
and 2) PTEN unmethylated sequence, forward 
5′-TATTAGTTTGGGGATTTTTTTTTTGT-3′ and re-
verse 5′-CCCAACCCTTCCTACACCACA-3′ (11). Both 
forms of PTEN were amplified with HotStarTaq (Qia-
gen, Tokyo, Japan) in 40 cycles at an annealing tem-
perature of 60°C. Aliquots of MS-PCR products (181 
bp, both PCRs) were analyzed on 2% agarose gel or 8% 
nondenaturing acrylamide gel and then stained with 
SYBR green nucleic acid gel stain (Gelstar, Lonza, Al-
lendale, NJ, USA).
For MS-PCR analysis, PTEN unmethylated primers 
amplified unmethylated product while PTEN methyl-
ated primers amplified only methylated product present 
in the ameloblastoma tissue. From our pilot study, DNA 
extracted from normal fibrous connective tissue was 
only amplified by unmethylated primers but not ampli-
fied by methylated primers. Thus, the methylated prod-
uct, if present, came from ameloblastoma tumor cells.
In our pilot study, we examined DNA in different cell 
lines and observed that the HeLa cell line had partial 
PTEN promoter methylation and PTEN expression. 
Therefore, HeLa DNA and distilled water were included 
as the positive and negative controls, respectively, in all 
experiments.
- RNA extraction and reverse transcription PCR 
(RT-PCR)
PTEN expression in the ameloblastoma primary cell 
cultures was examined using RT-PCR. Total RNA was 
extracted using the TRIzol reagent (Invitrogen, Singa-
pore), as per the manufacturer’s instructions. Single-
stranded complementary DNA (cDNA) was synthesized 
using the RevertAid First Strand cDNA Synthesis kit 
(Thermo Fisher Scientific, Waltham, MA, USA), as per 
the manufacturer’s instructions.
PTEN was amplified using HotStarTaq (Qiagen, To-
kyo, Japan) in 40 cycles at an annealing temperature 
of 55°C using the forward primer 5′-GGACGAACTG-
GTGTAATGATATG-3′ and reverse primer 5′-TC-
TACTGTTTTTGTGAAGTACAGC-3′ (12). To in-
vestigate the relative expression of a candidate gene, 
glyceraldehyde-3-phosphate dehydrogenase was used 
as an endogenous DNA control, with the sequences of 
the forward and reverse primers being 5′-CTCAGA-
CACCATGGGGAAGGTGA-3′ and 5′-ATGATCTT-
GAGGCTGTTGTCATA-3′, respectively. Both PCR 
mixtures contained PCR buffer (1×) (Qiagen, Tokyo, 
Japan), deoxynucleotide triphosphates (0.2 mM), the 
two primers (final concentration: 0.4 μM), HotStarTaq 
(1 U) (Qiagen, Tokyo, Japan), and template DNA (50 
ng). The PCR products (PTEN: 671 bp and GADPH: 
450 bp) were separated via gel electrophoresis on an 
8% nondenaturing acrylamide gel and stained with 
SYBR green nucleic acid gel stain (Gelstar, Lonza, 
Allendale, NJ, USA).
- Immunohistochemical staining of PTEN
In this experiment, the paraffin tissues were avail-
able in only 10 cases. Formalin-fixed paraffin embed-
ded blocks were cut into 3-μm thick sections. The 
histological sections of the relative samples were 
confirmed by a pathologist.  Immunohistochemis-
try was performed with an antihuman monoclonal 
antibody against PTEN Clone 6H2.1 (dilution 1:100, 
DAKO, Glostrup, Denmark) in Tris-HCl buffer an-
tibody diluent (Dako, Glostrup, Denmark) on the 
Ventana® Benchmarck XT (Ventana-Roche Diag-
nostics, Meylan, France) automated slide strainer in 
combination with the Ventana UltraView DAB IHC 
Detection Kit®. Before mounting, the sections were 
counterstained with Hematoxylin II® for 8 min, blu-
ing reagent® for 4 min, Hematoxylin II for 4 min, and 
bluing reagent for 4 min. To support the validity of 
staining and identify experimental artifacts, negative 
(omitting the primary antibody) and positive controls 
(normal breast tissue) were included in each run. Nu-
clear and cytoplasmic immunostaining of PTEN in 
ameloblastoma tumor cells were graded based on the 
presence or absence of protein staining.
- Statistical analysis
SPSS software for Windows version 22 (SPSS Inc., Chi-
cago, IL) was used to analyze all data. The effects of 
age and sex of the patients as well as the histological 
appearance of ameloblastoma on the PTEN methylation 
status and PTEN expression were investigated using the 
Pearson’s correlation coefficient test, chi-square test, 
and Fisher’s exact test. P < 0.05 was considered statisti-
cally significant.
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Results
- MS-PCR and immunohistochemistry of ameloblas-
toma tissues
We examined PTEN promoter methylation and whether 
it affects PTEN expression in ameloblastomas. PTEN 
promoter methylation was observed in 65% (13/20) of 
ameloblastoma samples (Table 1). The exemplified gel 
electrophoresis is demonstrated in Fig. 1. Ten samples 
of these ameloblastoma cases were investigated for im-
munohistochemical staining of PTEN. We found loss 
of PTEN expression in 3 of 5 (60%) ameloblastoma 
samples with PTEN promoter methylation while PTEN 
expression was present in 4 of 5 (80%) ameloblastoma 
samples with no PTEN promoter methylation (Table 1). 
Representative samples showing positive and negative 
immunostaining of PTEN were shown in Fig. 2.
- Association among PTEN promoter methylation, 
PTEN expression, and clinicopathological parameters
Table 1 shows the association between PTEN promoter 
methylation and PTEN expression in the ameloblastoma 
samples. No significant correlation was found between 
PTEN promoter methylation and PTEN expression (P = 
0.52). Furthermore, no correlation between PTEN pro-
moter methylation and age (P = 0.49), gender (P = 0.40), 
location (P = 0.62) and the histological appearance of am-
eloblastoma (P = 0.41) was demonstrated. Similarly, no 
correlation was observed between PTEN expression and 
age (P = 0.25), gender (P = 1.00), location (P = 0.51), and 
the histological appearance of ameloblastoma (P = 1.00). 
- MS-PCR and RT-PCR of primary ameloblastoma cell 
cultures
PTEN promoter methylation and PTEN expression were 
examined in four primary ameloblastoma cell cultures 
using RT-PCR (Fig. 3). Only 1 of 4 samples exhibited 
PTEN promoter methylation and showed no PTEN tran-
scription. PTEN promoter methylation was inversely 
correlated with PTEN transcription level in the remain-
ing ameloblastoma samples (75%) (Table 1).
Fig. 1: MS-PCR analysis of PTEN promoter in ameloblastoma samples.
PCR products amplified using primers specific for unmethylated (U) and methylated (M) forms. AM2, AM3, AM6, and AM7 show 
promoter methylation. The ladder in the left lane is a 100-bp marker.  Both methylated and unmethylated PCR products are 181 bp.
Positive control, Pos: HeLa cell line; negative control, Neg: distilled water; unmethylated PCR products, U; methylated PCR prod-
ucts, M.
Fig. 2: (A) Immunostaining of PTEN in ameloblastoma (streptavidin–biotin; 100×). PTEN immunoexpression is observed in cyto-
plasm and nucleus of ameloblastoma tumor cells (B) No expression of PTEN in ameloblastoma (streptavidin–biotin, 100×).
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Discussion
Ameloblastoma is considered the most common benign 
neoplasm of the jaw (1). To prevent local recurrence, pa-
tients with ameloblastoma are mostly treated with radi-
cal surgery. Understanding the molecular mechanisms 
that underlie the formation of this tumor may help in de-
veloping an alternative and novel treatment for its cure 
with minimal tissue or bone removal.
PTEN, a putative tumor suppressor gene, is commonly 
mutated in many types of human neoplasms (3). The 
protein product of PTEN, a lipid phosphatase, negative-
ly regulates the Akt signaling pathway, thereby stimu-
lating cell cycle arrest and apoptosis (13). Kumamoto 
and Ooya first reported that the PTEN level is signifi-
cantly lower in ameloblastic tumors than in tooth germs 
(14). The absence of PTEN in 33.3% of ameloblastoma 
samples was subsequently reported (10). These results 
suggest that the inactivation of PTEN may be involved 
in the molecular pathogenesis of ameloblastoma. In the 
present study, we investigated the possible role of PTEN 
promoter methylation and the associated loss of PTEN 
expression in a subset of ameloblastoma samples.
To the best of our knowledge, there have been no studies 
on PTEN promoter in ameloblastoma. Careful analysis 
of the PTEN promoter has been recommended because 
it shares a strong homology with the PTEN pseudogene 
(5). The genomic sequence of the highly conserved and 
processed PTEN pseudogene (GenBank accession num-
ber: AF040103, PTEN pseudogene; AF029308, Homo 
sapiens chromosome 9 duplication of the T-cell receptor 
β locus and trypsinogen gene families) is 98% identi-
cal to that of PTEN, and this identical sequence is com-
posed of an 841-bp region in the promoter region (15). 
In the present study, PTEN promoter methylation was 
performed using methylation-specific primers that do 
not amplify the highly homologous PTEN pseudogene 
because these primers lie outside the sequence homol-
ogy of the PTEN pseudogene.
Promoter methylation is reportedly one of the epigen-
etic mechanisms underlying the aberrant expression of 
tumor suppressor genes and contributing to the devel-
opment of various types of cancers. For example, the 
methylation of adenomatous polyposis coli promoter 
is reportedly associated with tumor in the colon and 
breasts (16). PTEN promoter methylation is also ob-
served in various types of cancers, including gastric, 
breast, colorectal, and lung cancer (7,8,17-20).
In the present study, PTEN promoter methylation was 
found in 65% (13/20) of the ameloblastoma samples. 
However, immunohistochemical staining of PTEN ex-
pression was performed in only 10 samples. Of these 
samples, 3 (60%) of 5 samples with PTEN promoter 
methylation were associated with loss of PTEN ex-
pression, whereas 4 (80%) of 5 samples without PTEN 
promoter methylation showed PTEN expression. PTEN 
promoter methylation and decreased PTEN expression 
were not significantly correlated, indicating that other 
genetic or epigenetic mechanisms possibly regulate 
PTEN expression, for example, genetic alterations, 
transcriptional silencing, post-transcriptional regula-
tion, and modification (21). Previously, PTEN exhibited 
high frequency of allelic losses (62%) in ameloblastic 
Fig. 3: MS-PCR and RT-PCR analyses of promoter methylation and mRNA expression of PTEN in primary ameloblastoma cell 
cultures. The upper and middle panels show MS-PCR results, whereas the bottom panel shows RT-PCR results. Arrows indicate the 
locations of the expected amplicons. GAPDH was used in RT-PCR as an internal control.
Standard 100 bp marker, M; positive control, Pos: HeLa cell line; negative control, Neg: distilled water; methylation-specific PCR, 
MS-PCR; reverse transcription polymerase chain reaction, RT-PCR; phosphatase and tensin homolog, PTEN; glyceraldehyde-
3-phosphate dehydrogenase, GAPDH; unmethylated PCR products, Unmet; methylated PCR products, Met.
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tumors (9). Moreover, Narayan et al. reported that 5 
(25%) of 20 samples of solid/multicystic ameloblastoma 
exhibited gene alterations in exon 5 of PTEN while no 
PTEN mutation was observed in normal tooth germs. 
However, associated protein expression was not exam-
ined in those samples (22). Based on the two-hit model 
(23), it may be possible that PTEN promoter methylation 
and allelic loss play a role in PTEN inactivation since 
PTEN is a tumor suppressor gene. It is also possible that 
PTEN promoter methylation, contributing to a decrease 
in protein expression, depends on the specific tumor 
type. Previous studies on lung and ovarian cancers did 
not see a correlation between PTEN promoter methyla-
tion and loss of protein expression (18,24).
Notably, in the present study, 2 (40%) of 5 samples 
with PTEN promoter methylation showed PTEN ex-
pression. This may be attributed to the partial meth-
ylation of PTEN at the promoter region. It has been 
proposed that translational inactivation involves a se-
ries of events requiring a sufficient DNA methylation 
level. The silencing process is then maintained by the 
spread of methylation (25). This is also supported by 
the presence of unmethylated bands in several samples 
following MS-PCR. However, these unmethylated 
bands also represent normal fibrous tissue stroma in 
the ameloblastoma samples.
Regarding the in vitro experiment, only 1 (25%) of 4 
primary ameloblastoma cell cultures showed promoter 
methylation and loss of PTEN transcription. This re-
sult is consistent with a previous study on breast can-
cer; none of the breast cancer cell lines exhibited PTEN 
promoter methylation (17). Lastly, the limitation of the 
present study is the small sample size that may not rep-
resent ameloblastoma cases and cell lines in general; 
thus, further studies with a larger sample size are re-
quired to confirm our findings.
In conclusion, PTEN promoter methylation was detected 
in a subset (58.3%) of ameloblastoma samples; however, 
it did not significantly contribute to decreased PTEN 
expression. Other genetic mechanisms possibly un-
derlie the loss of PTEN expression in ameloblastomas.
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